Moffitt logo

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Clinical Trials Search

Clinical Trial 20870

Cancer Type: Gynecological Tumor
Study Type: Treatment
NCT#: NCT05080946

Phase: N/A
Prinicipal Investigator: Jing-Yi Chern

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors

Summary

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers or immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Objective

Primary Objective: To evaluate the efficacy of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression (tumor-associated macrophages and T-regulatory cells) in the tumor at interval debulking surgery. Secondary Objectives: To evaluate the efficacy of aspirin for reducing tumor burden and tumor COX1/COX2 expression. Will also examine the efficacy of aspirin for reducing plasma inflammatory markers (IL-6 and p-selectin) and CA 125. Throughout the course of the investigation, additional relevant biomarkers may be evaluated. Tertiary Objectives: To monitor the safety and toxicity of aspirin use in this population. We will also compare patient-reported emotional distress (depression, anxiety), gastrointestinal (nausea and vomiting, gastroesophageal reflux, belly pain, gas and bloating, diarrhea), and other physical and cognitive symptoms (sleep quality and sleep-related impairment, fatigue, cognitive function, neuropathic pain, general pain, bruising) in ovarian cancer patients randomly assigned to aspirin versus placebo.

Treatments

Therapies

Medications

Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()

Inclusion Criteria

  • Patients that are greater than or equal to 18 years of age
  • Histology confirmed, or clinical suspicion of, invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma. Must be grade 2 or 3. Serous, endometrioid, or carcinosarcoma histology is acceptable. Mixed histology also acceptable.
  • Treatment naïve for this cancer diagnosis
  • Planned for neoadjuvant chemotherapy (platinum-based doublet with taxane +/- anti-VEGF antibody) for at least 3 but no more than 5 cycles followed by an interval debulking surgery. [Note: this study evaluates response while on neoadjuvant treatment. The final collection of specimen and questionnaire is at the time of surgery and immediate post-operative state. Therefore, there are no eligibility criteria related to treatment in the adjuvant setting (e.g., intraperitoneal treatment) and adjuvant therapy should proceed as the physician deems appropriate.]
  • Measurable disease as defined by RECIST 1.1, CT scan (with or without contrast) within 12 weeks of study enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0,1, or 2
  • Able to provide tissue biopsy (core or excisional) sufficient for diagnosis and biomarker analysis, may use outside archival tissue if available.
  • If currently using anti-coagulation medication, no contraindication for temporary stoppage of use during the study based on physician judgement
  • Willing and able to swallow pills without difficulty
  • Un-transfused platelet count > 100,000 cells
  • Willing and able to participate in all required evaluations and procedures in this study protocol (e.g. undergoing treatment, scheduled visits and examinations, serum testing, questionnaires, pill log/diary)
  • Absolute neutrophil count > 1.5 x 109 cells/L
  • Hemoglobin > 9.0 g/dL, may use transfusions and the value can be post-transfusion
  • Estimated creatinine clearance of > 30 mL/min, calculated using the formula Cockcroft-Gault [(140-age) x Mass (kg)/(72 x creatinine mg/dL)] x 0.85 for female
  • No severe hepatic impairment defined as AST or ALT elevation < 2.5 x institutional ULN, unless liver metastasis is present < 5 x ULN

  • Exclusion Criteria

  • Definite contraindication for either aspirin use or stopping current aspirin use based on physician’s clinical judgment
  • History of vascular event in the last 12 months (e.g., myocardial infarction or unstable angina, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant [serious or significant] arrhythmias, significant vascular disease, congestive heart failure or vascular interventions).
  • History of hypertensive crisis and/ or uncontrolled HTN, systolic blood pressure > 150 mmHg; diastolic blood pressure > 90mmHg. Patients must have blood pressure > Current or history of ulcers which prohibits aspirin consumption, severe hepatic failure, or acute or chronic renal disease where aspirin use is contraindicated
  • History of gastrointestinal or genitourinary bleeding or other bleeding diathesis or coagulopathy within 6 months prior to enrollment of study
  • Active diagnosis of reflux esophagitis
  • Other cancer diagnosis in the last 3 years other than non-melanoma skin cancer
  • Autoimmune disorder requiring systemic therapy
  • Chronic steroid use defined as 3 weeks in the past year or any length of time in the past 30 days.
  • Other aspirin or NSAID hypersensitivities or contraindications (e.g. allergy)
  • History of bariatric surgery
  • Currently pregnant at the Screening visit or planning on becoming pregnant during the study period
  • Patient unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with study medication.
  • Metabolism CYP2C9, known G6PD deficient patients

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    ;